RxDoctor Payments Data

Claudine Dumandan, MD

Cardiovascular Disease · Shenandoah, TXNPI 1508290776

Payments from drug & device makers

$5,037in general payments, 2019–2025

Across 180 payments — averaging $27.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Abbott$879
  • Novartis$565
  • Boehringer Ingelheim$550
  • AstraZeneca$485
  • Amgen$318
  • plus $960 from 13 others

What the payments were for

  • Travel & lodging$1,19324%
  • Food & beverage$3,84476%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,037 in reported general payments places this provider in the 55th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$92,799
Medicare patients
691
Services billed
1,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban324$272,012
EntrestoSacubitril/Valsartan118$94,052
XareltoRivaroxaban79$67,826
Repatha SureclickEvolocumab53$51,969
JardianceEmpagliflozin70$48,373
Repatha SyringeEvolocumab13$17,008
Dofetilide48$7,141
Metoprolol Succinate446$5,092
Atorvastatin Calcium335$3,552
Potassium Chloride169$2,675
PaceroneAmiodarone Hcl17$2,309
Rosuvastatin Calcium160$2,151
Ezetimibe68$1,501
Losartan Potassium134$1,176
Amiodarone Hcl68$1,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$116$272,012324 claims
NovartisEntresto$565$94,052118 claims
Johnson & JohnsonXarelto$153$67,82679 claims
Boehringer IngelheimJardiance$550$48,37370 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →